Genscript Biotech Corporation Capital Reinvestment Ratio
Genscript Biotech Corporation capital reinvestment ratio. Genscript Biotech Corporation (G51) has a Capital Reinvestment Ratio of 0.26x as of December 2025, meaning it reinvests 0% of its operating cash flow (€325.52 Million) in capital expenditures (€83.84 Million). Check Genscript Biotech Corporation total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Genscript Biotech Corporation (2016–2025)
Capital reinvestment ratio of Genscript Biotech Corporation from 2016 to 2025. This chart tracks Genscript Biotech Corporation's Capital Reinvestment Ratio across 5 annual periods. Also explore Genscript Biotech Corporation (G51) equity growth momentum to track the company's year-over-year net asset growth rate.
Genscript Biotech Corporation Capital Reinvestment Ratio by Year (2016–2025)
Genscript Biotech Corporation capital reinvestment ratio by year from 2016 to 2025. For the full cash flow conversion analysis, see Genscript Biotech Corporation cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.26x | €325.52 Million | €83.84 Million | ▼ -86.8% |
| 2024 | 1.96x | €75.65 Million | €147.92 Million | ▲ +749.2% |
| 2018 | 0.23x | €307.66 Million | €70.84 Million | ▼ -83.2% |
| 2017 | 1.37x | €21.37 Million | €29.21 Million | ▲ +406.6% |
| 2016 | 0.27x | €33.27 Million | €8.98 Million | — |